In addition to vaccines based on specific peptides, a potential approach to induce tumor recognition is the production of vaccines derived from whole tumor cells combined with immune-enhancing adjuvants (such as IFN-γ and GM-CSF), with interesting preliminary data in a cohort of STS [172]. The gene discussed is CSF2; the disease is telomere syndrome.